Sanofi looks to emerging target for multiple myeloma
GPRC5D targeting domain from Eureka, MSKCC adds to Sanofi’s growing oncology tool kit
Sanofi is adding another mechanism in multiple myeloma through a licensing deal with Eureka and Memorial Sloan Kettering that gives it access to an emerging target in the indication.
Sanofi (Euronext:SAN; NASDAQ:SNY) licensed non-CAR T rights to a human binding domain against GPRC5D from co-developers Eureka Therapeutics Inc. and Memorial Sloan Kettering Cancer Center (MSKCC) for an undisclosed upfront payment with the potential for $1 billion in milestones plus tiered royalties. ...